CCM
COLL icon

Cadence Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Cadence Capital Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-63,861
Closed -$1.12M – 309
2020
Q2 		$1.12M Buy
+63,861
New +$1.25M 0.16% 195

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cadence Capital Management's COLL Position: Q3 2020 in Review

Cadence Capital Management sold out of Collegium Pharmaceutical (COLL) in Q3 2020, closing a stake of 63,861 shares — an estimated $1.12M sold.

Cadence Capital Management first reported a position in COLL in Q2 2020 and held it in 1 quarter. The position peaked at $1.12M in Q2 2020. 140 funds tracked by Wall St. Rank hold COLL as of Q3 2020.

  • Cadence Capital Management reported no remaining Collegium Pharmaceutical position as of Q3 2020 after selling out during the quarter.
  • Cadence Capital Management sold 63,861 Collegium Pharmaceutical shares in Q3 2020, an estimated $1.12M.
  • Cadence Capital Management first reported a position in Collegium Pharmaceutical in Q2 2020 and held it in 1 quarter.
  • Cadence Capital Management's Collegium Pharmaceutical position peaked at $1.12M in Q2 2020.
  • 140 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.